Envista (NYSE:NVST) Price Target Lowered to $19.00 at Bank of America

Envista (NYSE:NVST) had its target price decreased by Bank of America from $22.00 to $19.00 in a research report released on Thursday morning, Benzinga reports. Bank of America currently has a buy rating on the stock.

A number of other research analysts have also weighed in on NVST. Evercore ISI dropped their price target on shares of Envista from $19.00 to $18.00 and set an outperform rating on the stock in a research report on Thursday. The Goldman Sachs Group cut their price target on shares of Envista from $20.00 to $17.50 and set a sell rating on the stock in a report on Friday, May 3rd. Needham & Company LLC restated a hold rating on shares of Envista in a report on Thursday. Stifel Nicolaus dropped their target price on shares of Envista from $20.00 to $18.00 and set a buy rating on the stock in a research note on Tuesday, July 30th. Finally, Morgan Stanley lowered shares of Envista from an overweight rating to an equal weight rating and decreased their price target for the stock from $33.00 to $21.00 in a research note on Friday, April 26th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Hold and an average target price of $19.14.

Envista Stock Down 1.9 %

Shares of Envista stock traded down $0.32 during trading hours on Thursday, reaching $16.18. The company’s stock had a trading volume of 4,446,997 shares, compared to its average volume of 2,442,982. Envista has a one year low of $15.15 and a one year high of $33.84. The company has a market capitalization of $2.78 billion, a P/E ratio of -22.47, a P/E/G ratio of 14.74 and a beta of 1.31. The stock’s fifty day simple moving average is $16.82 and its two-hundred day simple moving average is $19.49. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.93 and a current ratio of 2.27.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.16). Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The firm had revenue of $633.10 million for the quarter, compared to the consensus estimate of $646.88 million. During the same period in the previous year, the business earned $0.43 earnings per share. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. On average, research analysts forecast that Envista will post 1.15 earnings per share for the current year.

Hedge Funds Weigh In On Envista

A number of large investors have recently modified their holdings of NVST. Fifth Third Bancorp lifted its stake in Envista by 98.1% in the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after purchasing an additional 621 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Envista by 1,420.3% in the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock worth $52,000 after buying an additional 2,940 shares in the last quarter. Signaturefd LLC grew its position in Envista by 1,297.9% during the fourth quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock worth $63,000 after buying an additional 2,427 shares in the last quarter. Quadrant Capital Group LLC increased its stake in Envista by 538.0% in the 4th quarter. Quadrant Capital Group LLC now owns 3,209 shares of the company’s stock worth $77,000 after acquiring an additional 2,706 shares during the last quarter. Finally, Innealta Capital LLC purchased a new stake in shares of Envista in the 2nd quarter valued at about $78,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.